Interclean Shanghai

NICE Collaborates With Health Technology Evaluation Groups

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media PackNow

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

FDA Seeks Opinion on AI-Enabled Medical...

The U.S. Food and Drug Administration (US FDA) is...

FDA Approves Zenix Monitor-Defibrillator from ZOLL

ZOLL®, which happens to be an Asahi Kasei company...

MHRA in the UK Accelerates AI...

The Medicines and Healthcare Products Regulatory Agency (MHRA) from...

FDA Widens Early Alert Initiatives for...

The Food and Drug Administration (FDA) has gone on to...

In order to address issues including collaborating with regulators and assessing digital health technologies, the National Institute for Health and Care Excellence (NICE) will collaborate with five health technology assessment (HTA) organisations such as Canadian Agency for Drugs and Technologies in Health (CADTH), All Wales Therapeutics & Toxicology Centre, Australian Government Department of Health and Aged Care, Health Technology Wales, Healthcare Improvement Scotland.

The management of COVID-19-related tasks, including interactions with regulators, issue prioritisation, management of medications without a marketing authorization, preparation for HTAs, and economic modelling techniques, will be improved as the first area of focus.

Before an HTA is completed, the groups will explore how HTA methods could improve how existing technological and methodological issues are managed. To deal with these issues, the bodies will collaborate on methodological and scientific issues. Collaborations in the regulatory field will also receive attention. Agencies from the UK, Canada, and Australia will look for chances to strengthen their connections with regulatory and HTA bodies.

The parties will evaluate if exchanging HTA data is advantageous and look into whether conducting a pilot for a combined clinical assessment will be fruitful.

The organisations will also exchange data on developments in assessing digital health technologies like AI. The groups will meet four times a year to discuss how their activities are progressing. All members will also be present at an annual meeting to discuss accomplishments and set goals for the following quarter and beyond.

Meindert Boysen, head of international affairs at NICE, said that by collaborating, the HTA community and NICE can more effectively foresee, recognise, and address the key opportunities and challenges posed by advances in science and healthcare.

After years of productive informal cooperation, Boysen continued, he is thrilled that they have now formalised the partnership with important members of the international HTA community.

Latest stories

Related stories

FDA Seeks Opinion on AI-Enabled Medical Devices Regulation

The U.S. Food and Drug Administration (US FDA) is...

FDA Approves Zenix Monitor-Defibrillator from ZOLL

ZOLL®, which happens to be an Asahi Kasei company...

MHRA in the UK Accelerates AI Rollout in the NHS

The Medicines and Healthcare Products Regulatory Agency (MHRA) from...

FDA Widens Early Alert Initiatives for All Medical Devices

The Food and Drug Administration (FDA) has gone on to...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Translate »